Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Scientists at La Trobe University have created a world-first method to investigate "disordered" proteins in living cells, in ...

TAMPA — November marks National Alzheimer’s Disease Awareness Month. According to the Alzheimer’s Association, nearly 7 ...

Huntington Hospital recently renovated its two cardiac catheterization labs and unveiled new state-of-the-art diagnostic ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Huntington's Disease is one of the most devastating diseases out there and many people have never heard of it. Actor WIll ...

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating ...

Studies nationwide show overdose deaths have been on a steady decline the past few years. The West Virginia Department of ...

The Phase II DIMENSION study of Sage's dalzanemdor failed to meet its primary and secondary endpoints for treating Huntington ...

One couple thought they could not only keep a huge secret from their children, but also lie to their daughter about it and ...

After years of setbacks, biotechs are advancing treatments for Huntington’s disease, offering new hope as clinical studies ...

H.C. Wainwright says Sage Therapeutics (SAGE) faced “another setback” for as dalzanemdor failed to provide a signal on the primary or key ...